期刊文献+

慢性肾病与血脂异常 被引量:2

Research Review of Relationship between Chronic Kidney Disease and Dyslipidemia
在线阅读 下载PDF
导出
摘要 慢性肾病的发病率较高,我国40岁以上的患者在总人口数中已超过10%,但患病人群对于自身疾病的治疗率却极低,在我国仅为5%左右。慢性肾病可由多种因素引起,如生活习惯或饮食结构不合理等。本文分析了血脂异常的发病原因,并对当前慢性肾病与血脂异常关系的研究成果进行了综述,包括血脂异常与肾功能异常的关系,慢性肾病LDL-C及总胆固醇水平升高的病理机制,慢性肾病患者行血液透析治疗与LDL-C水平升高的关系,肾移植术后血脂代谢异常的特点。 Chronic kidney disease( CKD) has a higher incidence of a disease. In China,over the age of 40 patients are more than 10% in the total population,but the population for the treatment of disease is very low,only about 5% in our country. CKD can be caused by many factors,such as life style or diet structure unreasonable and so on. This paper analysed the reasons for the onset of dyslipidemia. The research about the relation between the current chronic kidney disease and dyslipidemia results were summarized,including the relationship between dyslipidemia and renal abnormalities,chronic kidney disease( CKD) LDL-C and pathological mechanism of elevated levels of total cholesterol,lines of hemodialysis patients with chronic kidney disease treatment and the relationship between elevated levels of LDL-C,the characteristics of blood lipid metabolic abnormalities after renal transplantation.
作者 袁婷 郭兆安
出处 《光明中医》 2015年第4期711-712,共2页 GUANGMING JOURNAL OF CHINESE MEDICINE
关键词 血脂异常 慢性肾病 研究综述 病因病机 病理机制 Dyslipidemia Chronic kidney disease Research review Etiology and pathogenesis Pathological mechanism
  • 相关文献

参考文献6

二级参考文献42

  • 1王涛,钟惠菊.游离脂肪酸与2型糖尿病及其心血管并发症[J].陕西医学杂志,2005,34(3):319-320. 被引量:6
  • 2陈明卫,王佑民,胡红琳,胡国平,刘玲,王长江,杨明功.血清肿瘤坏死因子α、游离脂肪酸以及抵抗素与2型糖尿病患者胰岛素抵抗的关系[J].中国糖尿病杂志,2006,14(1):4-6. 被引量:26
  • 3Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量:117
  • 4National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal System, USRDS 1998 Annual Data Report. Bethesda,Md:National Institutes of Health, National Institutes of Diabetes and Kidney Diseases,1998.
  • 5Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care:a report from the An- tihypertensive and Lipid-Lowering Treatment to Prevent Heart At- tack Trial( ALLHAT). Am J Kidney Dis,2008,52(3) :412-424.
  • 6Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodonto1,2008,79 ( 8 Suppl) : 1544-1551.
  • 7Drew BG,Fidge NH ,Gallon-Beaumier G,et al. High-density lipo- protein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylafion. Proc Nail Acad Sci U S A,2004,101 (18) :6999-7004.
  • 8Murphy A J, WooUard K J, Hoang A, et al. High-Density Lipopro- tein Reduces the Human Monocyte Inflammatory Response. Arte- rioseler Thromb Vase Bioi,2008,28( 11 ) :2071-2077.
  • 9Tall AR,Yvan-Charvet L,Terasaka N ,et al. HDL,ABC transport- ers, and cholesterol efflux: implications for the treatment of ather- osclerosis. Cell Metab,2008,7 ( 5 ) : 365 -375.
  • 10Murphy A J, Chin-Dusting JP, Sviridov D, et al. The Anti Inflam- matory Effects of High Density Lipoproteins. Curt Med Chem, 2009,16(6) :667-675.

同被引文献26

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部